OUR FACILITIES
WILL REMAIN OPEN & OPERATIONAL DURING THE COVID-19 PANDEMIC

528
Active Clinical Trials
7
Commercial Products
385,000+
Shipments
150+
Countries
Box-for-1MARCH2021-1  ESG-Box 

Upcoming Events View All

APR26

GCSG 2021 US Virtual Conference

Date: April 26-29, 2021

Location: Virtual Event

MAY4

World Vaccine Congress Washington

Date: May 4-6, 2021

Location: Virtual Event

The Latest From Our Blog View All

Cryoport Systems Now Supporting 7 Commercial Therapies Globally

We’re celebrating big news from two Cryoport Systems valued clients: bluebird bio and Bristol Myers-Squibb announced FDA approval of their cell therapy Abecma, a personalized immune therapy for patients with multiple myeloma.

More Commercial Activity, More Commercial Filings: Good News Ahead for Regenerative Medicine

While the pandemic continues to disrupt many industries, including regenerative medicineit’s not all bad news -- in fact, there are likely some bright spots ahead for the industry this year.

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC

Exciting News! Cryoport, Inc., our parent company, has expanded its family of companies in continuing to support temperature controlled supply chain solutions for the life sciences industry. Learn More